Sitagliptin Add-On To Metformin Plus Sulphonylurea Combination Therapy: The Efficacy Of Triple Therapy On Metabolic and Glycemic Control İn Type 2 Diabetes
Abstract
©Copyright 2021 by Anatolian Journal of Family Medicine Available online at www.anatoljfm.org INTRODUCTION Diabetes is a complex, chronic entity that requires strategies to reduce multiple risk factors and continuous medical care well beyond glycemic control.[1] Oral antidiabetic drugs (OAD) are continuously being approved for the treatment of type 2 diabetes, leading to more diverse combination possibilities before treatment intensification and forefront combination therapies. The American Diabetes Association (ADA) Standards of Medical Care in Diabetes 2019 guideline advises a combination therapy of two drugs if hemoglobin A1c (HbA1c) levels are >1.5% of the aimed rate. Meanwhile, The American Association of Clinical Endocrinologists and The American College of Endocrinology (AACE/ACE) 2019 guidelines advise for double drug treatment as a first-line approach in patients with ≥7.5% HbA1c.[1,2] Data on the outcomes of adding a third OAD into the double treatment, including metformin, Objectives: This study aimed to evaluate the efficacy of sitagliptin add-on metformin and sulphonylurea combination therapy in type 2 diabetic patients with insufficient glycemic control.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.